期刊文献+

流感疫苗中间品—鸡胚尿囊病毒液质量控制的研究 被引量:2

Quality Control in Intermediate Products of Influenza Vaccine—Chicken Embryo Virus Allantoic Fluid
下载PDF
导出
摘要 为建立流感疫苗中间品—鸡胚尿囊病毒液质量控制点提供依据。用鲎试剂法、微生物限度检查法、沙门菌检查法检测流感疫苗中间品—鸡胚尿囊病毒液的细菌内毒素含量、微生物限度及沙门菌。在300份鸡胚尿囊病毒液中,细菌内毒素含量大于5EU/mL的阳检率为5%;微生物限度检查中小于10个/mL细菌菌落数的占78.67%,小于10个/mL霉菌菌落数的占80.67%,小于10个/mL酵母菌菌落数的占88.67%。沙门菌属的阳检率为4%,其中未检出A~F群的沙门菌。对流感疫苗中间品—鸡胚尿囊病毒液进行细菌内毒素,微生物限度及沙门菌检测可避免不合格尿囊病毒液进入后续生产,污染后续中间品。 A quality control point of intermediate products of influenza vaccine--chicken embryo virus allantoic fluid (IPIV) was established in order to provide a foundation. The bacterial endotoxin was tested with TAL, checking limits of microorganisms (CLM) , and Salmonella checking methods. The results showed that in the 300 IPIV samples the positive rate of bacterial endotoxin of more than 5 EU/mL was 5% , bacterial colonies of less than 10 cfu/mL with CLM was 78.67% , mould of less than 10 cfu/mL was 80.67% , and yeast of less than 10 efu/mL was 88.67%. And the positive rate of Salmonella was 4% , and none belonged to A - F groups. Therefore, with the test of bacterial en- dotoxin, CLM, and Salmonella checking could avoid unqualified virus allantoic fluid enter into the follow-up products to pollute the follow-up intermediate products.
出处 《微生物学杂志》 CAS CSCD 2009年第3期42-45,共4页 Journal of Microbiology
关键词 流感疫苗 鸡胚尿囊病毒液 细菌内毒素 微生物限度 沙门菌 nflucnza virus vaccine chick embryo allatoic fluid bacterial endotoxin
  • 引文网络
  • 相关文献

参考文献2

二级参考文献17

  • 1Chen Z, Matsuok, Asanumah, et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin-and neuraminidase-expressing DNAs. Vaccine, 1999,17(7-8) :653-659.
  • 2Levi R, Aboud-Pirok E A, Leclerc C, et al. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine, 1995,13:1353-1359.
  • 3John J T, Robert F B,Gale E S,et al. Evaluation of a recombinant Hemagglutinin expressed in insect cells as an influenza yaccinc in young and elderly adults. J Infect Dis, 1996,174:1467-1470.
  • 4Parkin N T, Chiu P, Coelingh K. Genetically engineered live attenuated influenza A virus vaccine candidates. J Virol, 1997,71: 2772-2778.
  • 5Hilbert A K, McCarthy L, Mills K H. Biodegradable microspheres containing influenza a vaccine Immune response in mice. Vaccine, 1999,17:1065-1073.
  • 6Robert B B. A review of attenuation of influenza virus by genetic manipulation. Am J Respir Crit Med, 1995,152:72-75.
  • 7Arnon R , Levi R. Synthetic reconbinant vaccines against viral agents. Int Arch Allergy Immunol, 1995,108: 321-326.
  • 8Harley V R, Mather K A,Power B E,et al. Characterization of an avian influenza virus nucleoprotein expressed in E. coli and in insect cells. Arch Virol, 1990,113: 267-277.
  • 9Mather H A, White J F, Hudson P J, et al. Expression of influenza neureminidase in baculovirus-infected cells. Virus Res, 1992,26:12715.
  • 10Lakey D L, Treanor J, Betts R F, et al. Recombinant Baculivirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis, 1996,174:838-841.

共引文献51

同被引文献12

引证文献2

二级引证文献30

;
使用帮助 返回顶部